Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00368836
Other study ID # 433
Secondary ID R42HL086316-01
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date January 2006
Est. completion date June 2008

Study information

Verified date June 2021
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A pulmonary embolism (PE) is a blockage in one of the arteries of the lungs, and is usually caused by a traveling blood clot. The D-dimer blood test is currently used to diagnose PEs, but it is not always accurate for individuals who have recently undergone surgery or who have inflammatory-provoking diseases. The purpose of this study is to evaluate the effectiveness of the Carboximeter, a new PE diagnostic device that measures carbon dioxide (CO2) and oxygen (O2) output, in individuals at risk for developing PEs.


Description:

PE is the second leading cause of sudden, unexpected death in the United States. In 90% of the cases, it is caused by deep vein thrombosis: a blood clot forms in a vein, travels through the bloodstream, and lodges in the lungs. PE symptoms vary, and can include cough, shortness of breath, chest pain, rapid breathing, or increased heart rate. Some medical procedures and diseases activate inflammation and blood coagulation, thereby making individuals more vulnerable to PE. Surgery, kidney dialysis, cancer, connective tissue diseases, infectious diseases, and being over 70 years old put individuals at increased risk for developing PEs. A common screening test for PE is the D-dimer blood test, which measures the level of a specific protein that is released following a PE. This test, however, has proven to be an unreliable diagnostic tool for individuals who are at high risk for PE. A more reliable diagnostic tool is needed. The Carboximeter is a new device that measures the ratio of CO2/O2 pressure in an individual's expired breath. By monitoring these components, researchers may be able to accurately diagnose PEs in high risk individuals. The purpose of this study is to evaluate the effectiveness of the Carboximeter at diagnosing PE in individuals at risk for developing PEs. This study will be conducted in two phases. In Phase I, CO2/O2 ratio and D-dimer levels will be measured prior to and following orthopedic or cancer-related surgery in 100 individuals at risk for developing PEs. In Phase II, the same measurements will be carried out on 350 high risk individuals who are experiencing PE symptoms. These individuals will also undergo computed tomography (CT) angiography and venography, in which blood flow will be visualized using x-rays. A follow-up evaluation will occur 30 days later. If any participant from Phase I or II experiences a PE or a medical condition that affects their lungs, such as asthma or chronic obstructive pulmonary disease (COPD), researchers may schedule a follow-up evaluation to obtain repeat measurements.


Recruitment information / eligibility

Status Completed
Enrollment 475
Est. completion date June 2008
Est. primary completion date April 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Phase I Inclusion Criteria: - Experienced or is scheduled for at least one of the following: 1. Hip or knee replacement surgery 2. Hip or acetabular fracture surgery 3. Pelvic fracture 4. Decompression for spinal stenosis surgery 5. Scoliosis corrective surgery 6. Craniotomy surgery for brain tumor 7. Surgery for any of the following cancers: bladder, colon (including caecum and rectum), kidney, ovary, pancreas, or uterus Phase I Exclusion Criteria: - Currently undergoing treatment for PE or has received treatment for PE in the 4 weeks prior to study entry - Hospitalized for fewer than 2 days - Anatomic abnormality that would prevent use of a mouthpiece - Living situation that makes follow-up difficult (e.g., homeless, incarcerated) Phase II Inclusion Criteria: - Clinical suspicion of PE with signs or symptom suggestive of PE within 24 hours of presentation and at least one risk factor for PE, as defined under the criteria as outlined in this protocol - CTA of pulmonary arteries ordered by clinical care providers - 18 years or older or an emancipated 17 year old - Written informed consent Phase II Exclusion Criteria: - Hemodynamic instability, including patients with a systolic blood pressure less than 90 mm Hg - Severe respiratory distress or the inability to breathe room air without the sensation of severe dyspnea - Pulse oximetry reading that declines more than 10% when exogenous oxygen is discontinued with accompanying worsening or new dyspnea - Intubated - Cannot breathe through the mouth owing to anatomic, physical or mental limitation - No fixed address, no telephone number, are from out of town or have other reason to suspect difficulty with follow-up - Incarceration - Known active tuberculosis - Prior PE or DVT with history of medical noncompliance with oral anticoagulation therapy based upon a history of unplanned subtherapeutic INR measurements (less than 1.5) - Active PE within previous 6 months and currently under treatment with anticoagulation - Pregnant - Disallowed medications: treatment with any fibrinolytic agent within 48 hours prior to enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BreathScreen PE
One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level

Locations

Country Name City State
United States Carolinas Medical Center Charlotte North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Heart, Lung, and Blood Institute (NHLBI), WFD Ventures Incorporated

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kline JA, Hogg M. Measurement of expired carbon dioxide, oxygen and volume in conjunction with pretest probability estimation as a method to diagnose and exclude pulmonary venous thromboembolism. Clin Physiol Funct Imaging. 2006 Jul;26(4):212-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement Median postoperative change in end tidal CO2/O2 ratio calculated as 100% * [(postoperative-preoperative)/(preoperative)] Pre-op measurement: the morning of surgery. Post-op measurement: the latter of postoperative day 3 or hospital discharge
Primary Phase II: Probability of Pulmonary Embolism Diagnosis by D-dimer Alone vs. D-Dimer Plus CO2/O2 for Pulmonary Embolism Diagnosed by CT Scan. D-dimer > 499 ng/ml, etCO2/O2 < 0.28, Pulmonary Embolism diagnosed by CT scan Measured at 45 days
See also
  Status Clinical Trial Phase
Recruiting NCT05050617 - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Terminated NCT03002467 - Impact Analysis of Prognostic Stratification for Pulmonary Embolism N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2